Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review found that combined oral contraceptives and spironolactone are effective treatments for adult acne in women, but noted that oral contraceptives increase the risk of venous thromboembolism and require individual risk assessment before use.

This review discusses the impact, pathophysiology, and health risks of obesity and the metabolic syndrome in polycystic ovarian syndrome, emphasizing the potential life-saving benefits of recognition and treatment, but it reports no new results.

In this preliminary study, women with facial hirsutism treated with topically applied finasteride cream showed a significant decrease in hair growth and thickness compared to placebo, without adverse effects.

This article reviews the use of hormonal therapies in dermatology, specifically focusing on their pathophysiologic rationale, indications, commonly used drugs, and pretreatment evaluations, and it reports no new research findings.

This chapter reviews various antiandrogens and androgen inhibitors, detailing their mechanisms, uses, and side effects, with a focus on spironolactone, finasteride, dutasteride, and oral contraceptives.

This article outlines common and serious causes of excessive body hair in women, noting that benign conditions like polycystic ovarian syndrome are treatable, while dangerous causes require swift medical attention; it reports no new results.

The document concludes that individualized treatment and lifestyle changes are important for managing menopause symptoms and health risks.

This article reviews adolescent sexual behavior and emphasizes the importance of hormonal contraception for sexually active teenagers, suggesting that health care providers play a crucial role in addressing their reproductive needs.

This source outlines various antiandrogen and androgen inhibitor drugs used to treat cutaneous disorders of hyperandrogenism, detailing their mechanisms, uses, dosages, and side effects, with emphasis on spironolactone, finasteride, dutasteride, and oral contraceptives.

This study found that a low-dose oral contraceptive containing dienogest provides effective contraception, improves cycle stability, and may reduce excessive scalp and skin oiliness, with high user satisfaction.

This study observed that new trienone compounds consistently showed higher 5alpha-reductase inhibitory activity compared to corresponding dienones across various biological models.

Hormonal contraceptives and related compounds can increase health risks like thrombosis and affect sexual function.

This study suggests that spironolactone may cause hormonally associated vestibulodynia and female sexual arousal disorder, with symptoms improving after discontinuation and use of a topical estrogen/testosterone gel.

In this study, Diane treatment in women with androgenetic alopecia led to normalization of hormone levels and improved hair condition, including less greasiness and reduced hair loss.

This study found that topical γ‐Oryzanol significantly stimulated sebaceous gland cell activity and sebum production in rats.

In this study, a newly designed protein degrader targeting androgen receptors showed promise in reversing hair regrowth inhibition in a mouse model of androgenetic alopecia, suggesting potential as a novel and safe treatment strategy.

This article reviews the skin changes that can occur with hormonal contraceptive use and highlights various mechanisms and potential treatment strategies but reports no new clinical results.

In this study, a combined treatment of Androcur and Diane improved acne, seborrhea, hirsutism, and androgenic alopecia in women to varying degrees over two years.

This review discusses the 2011 publications on the side effects of sex hormones and related compounds, without reporting new clinical results.

Spironolactone helps prevent swelling caused by minoxidil in women with hair loss.

This consensus report reviews current knowledge and identifies knowledge gaps concerning the various health aspects of polycystic ovary syndrome, without presenting new clinical findings.

This guideline from the Endocrine Society recommends using the Rotterdam criteria for diagnosing polycystic ovary syndrome and outlines first-line treatments, emphasizing hormonal contraceptives and lifestyle intervention.

This paper reviews the diagnostic criteria, etiological factors, and treatment approaches for PCOS, highlighting the importance of considering metabolic issues such as insulin resistance and obesity, but reports no new findings.

This review discusses the epidemiology, causes, diagnosis, and management of hirsutism in women, noting that effective treatment requires addressing the root cause as well as the hair growth.

This review discusses the roles of androgens and estrogens in skin functions and disorders, and highlights the use of estrogen-progestin treatments and anti-androgens in managing hirsutism and acne, without reporting new results.

This study found that lifestyle interventions improved body composition, hyperandrogenism, and insulin resistance in women with PCOS, but did not affect glucose tolerance, lipid profiles, or clinical reproductive outcomes.

This review discusses the diagnosis and treatment of hirsutism, emphasizing that a systematic evaluation can determine its cause, while combination therapy effectively manages the condition for most patients.

This article discusses treatments for hirsutism and acne in women with polycystic ovary syndrome, suggesting that lower doses of current medications maintain efficacy while reducing cost and side effects, but reports no new clinical results.

This review discusses recent advancements in understanding and managing congenital adrenal hyperplasia, including improvements in screening, diagnostics, and potential genetic and cell-based treatments, but reports no new clinical findings.

This study suggests that antiandrogens may slightly reduce hirsutism severity compared to placebo, but evidence is weak and their relative efficacy remains uncertain.